Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
This requirement was to develop a rapid and effective therapy against infection by developing an ovine immunoglobulin treatment against the spike protein of Covid 19.
Additional information:
PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health within the scope of the Civil Contingencies Act 2004 (CCA 2004). This urgent requirement is in response to the COVID -19 outbreak for the research of therapeutic antibodies.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| The Native Antigen Company | 07386339 | £26,523 | - |
Government spending data: This supplier has received £55,949 in 5 payments (over £25k) from Department of Health and Social Care (2021-03-29 to 2021-03-29). View full payment history →